Senate Patent Bill Leaves Industry Still Wanting PTO Process Reforms
This article was originally published in The Pink Sheet Daily
Executive Summary
But Judiciary Committee Chairman Grassley, one of the bipartisan measure’s cosponsors, said he would try to address biopharma industry’s concerns about abuse of the inter partes review process.
You may also be interested in...
Senate Bill Takes Targeted, MedTech-Supported Approach To Patent Trolls
The STRONG Patents Act includes multiple provisions that device and biotech firms say would strengthen the patent system and appropriately take a targeted approach to patent trolls. But the tech industry favors stronger measures to fight trolls that device companies say would weaken the overall patent system.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.